This drug was approved quite a long time ago for "bipolar-depression," and has now been approved for plain old garden variety depression, uh, make that "treatment resistant" garden-variety depression which seems to be about 70% of depression because, well, the treatment psychiatry routinely uses DON'T work. Nope antidepressants routinely don't work, so now they want... Continue Reading →
The Case Against Eli Lilly: Zyprexa
Eli Lilly and Company’s rap sheet as a public menace is so long that for Lilly watchers to overcome the “banality-of-Lilly-sleaziness” phenomenon, the drug company must break some type of record measuring egregiousness. Lilly obliged earlier this year, receiving the largest criminal fine ever imposed on a corporation.
It’s the Cymbalta stupid
From OpEDNews the lastest criminal activity on Eli Lilly's part. I don't have any commentary. Martha Rosenberg does a fine job without my adding my two cents: Many are outraged that Eli Lilly gave nonprofits $3.9 million in grants last year for medical courses to "educate" doctors about the pain-and-fatigue ailment fibromyalgia--more than it spent... Continue Reading →
AstraZeneca makers of Seroquel want to “protect” us by withholding information about the dangers of the drug
This you've got to read!! From the St. Petersburg Times: AstraZeneca, maker of the blockbuster antipsychotic Seroquel, is battling to keep information about the drug out of the public's view … for the public's own good. This month in Orlando, lawyers for the drugmaker will argue that unsealing company documents, including unpublished clinical trial data... Continue Reading →
Pushing drugs pharma style
From America Public Media Radio the program The Story: Shahram Ahari believes that the relationship between pharmaceutical companies and doctors can compromise the health of patients. Shahram knows what he's talking about: he was a drug rep with Eli Lilly, where he learned how to entice doctors with gifts, slanted statistics, and psychological profiles. He... Continue Reading →

You must be logged in to post a comment.